Celgene International Sàrl (Nasdaq:CELG) today announced that results from a clinical study of ABRAXANE (paclitaxel albumin-bound particles for injectable suspension) in combination with gemcitabine in 67 patients with previously untreated advanced pancreatic cancer were published in an online article by the Journal of Clinical Oncology ahead of print.
After the first phase of the study, the recommended Phase II dose was 125 mg/m2 of ABRAXANE followed by 1000 mg/m2 of gemcitabine on days 1, 8 and 15 of every 28-day cycle.
In Phase II, almost half of the patients responded (overall response rate was 48% (21/44)) and two-thirds experienced disease control (disease control rate was 68% (30/44)). The median progression-free survival was 7.9 months (95% CI: 5.8, 11.0) and the median overall survival (OS) was 12.2 months (95% CI: 8.9, 17.9). The one-year survival rate for patients was 48%.